| Literature DB >> 23945675 |
Fabiola Gutierrez-Orozco1, Mark L Failla.
Abstract
Mangosteen (Garcinia mangostana L.) is a tropical tree native to Southeast Asia that produces a fruit whose pericarp contains a family of tricyclic isoprenylated polyphenols referred to as xanthones. Numerous in vitro studies have shown that these xanthones possess anti-oxidant, anti-proliferative, pro-apoptotic, anti-inflammatory and anti-carcinogenic activities. Aggressive marketing of such health promoting benefits has resulted in mangosteen's classification as a "superfruit". This has led to sales of mangosteen containing beverages in USA alone exceeding $200 million in 2008 despite very limited animal and human studies. This review will (a) critically address recent reports of in vivo studies on the bioavailability and metabolism of mangosteen xanthones, (b) update the in vitro and in vivo data on anti-cancer and anti-inflammatory activities of mangosteen xanthones, and (c) suggest needed areas of inquiry regarding the absorption, metabolism and efficacy of mangosteen xanthones.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23945675 PMCID: PMC3775248 DOI: 10.3390/nu5083163
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Chemical structures of two most abundant xanthones in mangosteen.
Figure 2Number of publications related to mangosteen and their xanthones from 1980 to 2013. Search words: mangosteen, xanthones. Search performed on April 24 2013, including ahead of print publications. Databases: Pubmed, Science Direct, Google Scholar, Scirus.
Available reviews on chemical properties and bioactivities of xanthones in mangosteen.
| Chemical properties | Biological activities | Reference |
|---|---|---|
| natural and synthetic derivatives of xanthone | enzyme modulation, anti-tumor activity, anti-microbial, central nervous system(CNS) depressants, CNS stimulants, neurological disorders, anti-convulsant, analgesic, anti-arrhythmic, anti-hypertensive, anti-inflammatory, anti-allergic and immunomodulatory activities | [ |
| xanthones isolated from pericarp, whole fruit, trunk, leaves and branches | anti-oxidant, anti-tumor, anti-inflammatory, anti-allergic, anti-bacterial, anti-fungal, anti-viral and anti-malarial activities | [ |
| structural characterization of mangosteen xanthones in whole fruit, stem, aril, seeds, heartwood, leaves | anti-oxidant, anti-bacterial, anti-fungal, anti-malarial, anti-HIV, cytotoxic, aromatase inhibitory, anti-cancer and anti-inflammatory activities | [ |
| chemical constituents and methods of isolation from pericarp, whole fruit, stem, aril, seeds, heartwood, leaves | anti-oxidant, anti-fungal, anti-bacterial, cytotoxic, anti-histamine, anti-HIV, CNS-depressant, cardiovascular, anti-inflammatory and anti-ulcerative activities | [ |
| xanthones from mangosteen extracts | anti-cancer, anti-inflammatory, pro-apoptotic, cell cycle arresting, anti-invasive and anti-metastatic activities | [ |
Figure 3Transport and metabolism of mangosteen xanthones across intestinal epithelium. MG: xanthones; MG-X: xanthone phase II metabolites; MGY,Z: bioconversion products of xanthones.
In vivo anti-tumorigenic activities of mangosteen xanthones.
| Cancer cell type | Animal model | Tested compound | Delivery route | Dose | Outcomes | Reference |
|---|---|---|---|---|---|---|
| BJMC3879 (murine mammary adenocarcinoma) | Balb/c | panaxanthone (75%–85% α-MG, 5%–15% γ-MG) | diet | 5000 ppm | suppression of tumor volume and lung metastasis; decreased microvessel density | [ |
| BJMC3879 (murine mammary adenocarcinoma) | Balb/c | α-MG | subcutaneous | 20 mg/kg/day | decreased tumor growth and metastatic expansion; increased apoptosis; activation of caspase-3; decreased microvessel density; cytochrome c release from mitochondria; cell cycle arrest | [ |
| GBM8401 (human malignant glioblastoma) | nude Balb/cA-ν (ν/ν) | α-MG | intraperitoneal | 2 mg/kg/day | inhibition of tumor growth by 50%; increased phosphorylation of AMPK; induction of autophagy | [ |
| 22Rv1 (human prostate carcinoma) | Athymic nu/nu mice | α-MG | oral gavage | 100 mg/kg 5x/week | decreased tumor growth | [ |
| COLO205 (human colorectal adenocarcinoma) | Athymic NCr nu/nu mice | mangosteen pericarp extract containing 48 mg α-MG and 6.4 mg γ-MG per gram of extract | intratumorally | 0.024–3.0 mg per tumor | complete suppression of tumor growth at 3 mg extract/tumor; apoptotic cells, nuclear fragmentation and chromatin condensation; activation of caspases-3 and -8 | [ |
| HCT116 (human colorectal carcinoma) | Athymic NCR nu/nu nude mice | extract of mangosteen pericarp (81% α-MG and 16% γ-MG) | diet | 0.25% and 0.5% extract: food ratio (wt/wt) | inhibition of tumor growth; fewer blood vessels in tumor | [ |
| NL-17 (murine colon adenocarcinoma) | Balb/c | pericarp methanolic extract (25% α-MG) | intraperitoneal | 100–200 mg/kg | reduced tumor mass by 50%–70% | [ |
| Her2/CT26 cells (murine colon carcinoma) | Balb/c | α-MG | oral | 20 mg/kg | reduced subcutaneous growth | [ |
| HT-29 (human colon adenocarcinoma) | Athymic Balb/c | α-MG | diet | 900 mg/kg | 40% reduction in tumor mass; decreased Bcl-2 and β-catenin | [ |
|
| ||||||
| Chemically-induced (1,2dimethylhydra-zine) colon cancer | F344 rats | α-MG | diet | 0.02% and 0.05% in CE-2 basal diet | inhibition of induction and development of ACF; decreased dysplastic foci and β-catenin accumulated crypts; lower proliferating cell nuclear antigen in colon | [ |
In vitro pro-apoptotic and anti-proliferative activities of mangosteen xanthones.
| Cell type | Tested compound | Dose | Outcomes | Reference |
|---|---|---|---|---|
| BJMC3879 (murine mammary adenocarcinoma) | α-MG | 8 µM | induction of apoptosis; cell cycle arrest; activation of caspase-3 and -9; loss of mitochondrial potential | [ |
| PC3, and 22Rv1 (human prostate carcinoma) | α-MG | 2.5–15 µM | suppressed cell viability and colony formation; cell cycle arrest; activation of caspase-3 | [ |
| COLO205 (human colorectal adenocarcinoma) | mangosteen extract: 48 mg α-MG and 6.40 mg γ-MG/g extract | 30 µg/mL | induction of apoptosis; activation of caspase-3 and -8; release of mitochondrial cytochrome c | [ |
| HCT116 (human colorectal carcinoma) | extract of mangosteen pericarp (81% α-MG and 16% γ-MG) | 10–20 µg/mL | reduced cell viability; increased activities of caspase-3/7 and-9; loss of mitochondrial potential; enhanced activity of MAPK/ERK, Myc/Max and p53 signaling; increased JNK; decreased NF-κB | [ |
| NL-17 (murine colon adenocarcinoma) | pericarp methanol extract (25% α-MG) | >25 µg/mL | anti-proliferative activity | [ |
| HT-29 (human colon adenocarcinoma) | α-MG | 6–12 µM | anti-proliferative activity; decreased Bcl2 and β-catenin | [ |
In vitro anti-inflammatory activities of mangosteen xanthone.
| Cell type | Pro-inflammatory insult | Tested compound | Dose | Outcomes | Reference |
|---|---|---|---|---|---|
| Human U397 macrophage-likecells and primary adipocytes | LPS (100 µg/L) for 3 h | α- and γ-MG | α and γ-MG (2 h-pretreatment) with 10 or 30 µmol/L | α- and γ-MG decreased expression of IL-6, TNF-α, IFN-γ-inducible protein (IP)-10 in macrophage-like cells; decreased phosphorylation of MEK, JNK, ERK and p38; only γ-MG pretreatment attenuated LPS-mediated IκBα degradation; α- and γ-MG pretreatment decreased phosphorylation of c-Jun, Elk-1 and ATF-2; α- and γ-MG attenuated LPS-induced PPAR-γ suppression; γ-MG reduced inflammation and insulin resistance in adipocytes | [ |
| Human primary adipocytes | LPS,10 µg/L for 3 h | α-MG and γ-MG | α- or γ-MG (24 h pretreatment with 3 µmol/L) | α- and γ-MG attenuated LPS-induced inflammatory gene expression of TNF-α, IL-1β, IL-6, IL-8, MCP-1, and Toll-like receptor-2; α- and γ-MG decreased MAPK activation by suppressing phosphorylation of JNK, p38, and ERK; γ-MG attenuated IκBα degradation and NF-κB activation induced by LPS; xanthones inhibited phosphorylation of c-jun and transcriptional activity of AP-1; γ-MG blocked LPS-induced suppression of PPARγ (peroxisome proliferator-activated receptor γ) and its target genes | [ |
| Human U397 macrophage-like cells | LPS (0.1 ng/mL) for 4 h | α-MG | 6–12 nM for 30 min | α-MG attenuated LPS-stimulated TNF-α secretion by U937 macrophage-like cells and suppressed expression of genes related to immune responses and inflammatory processes such as cytokine production, Th1 and Th2 differentiation, and IL-1 signaling; α-MG decreased activation of p38, ERK1/2, JNK, STAT1, c-Fos and c-Jun | [ |
| Human cells: primary monocyte-derived macrophages (MDM); macrophage-like THP-1, hepatic HepG2, enterocyte-like Caco-2, and HT-29 colon adenocarcinoma | LPS (100 ng/mL for MDM and HT-29, 0.1 ng/mL for THP-1); PMA (50 ng/mL for HepG2); IL-1β (5 ng/mL for Caco-2) | α-MG | 4.5–10 µM (pretreatment for various times) | inhibition of IL-8 secretion by Caco-2, HT-29 and THP-1 cells; inhibition of TNF-α by HepG2 cells; stimulation of TNF-α by primary MDM cells | [ |
| Murine RAW 264.7 macrophage-like | LPS (100 µg/mL) | pericarp ethanol extract, α- and γ-MG | pericarp ethanol extract, (3–100 µg/mL), α- and γ-MG (3–100 µM) | α-MG and γ-MG inhibited NO and PGE2 production with moderate inhibitory effects on secretion of TNF-α and IL-4; expression of iNOS and COX-2 mRNA suppressed by α-MG; γ-MG inhibited transcription of iNOS | [ |
| Murine RAW 264.7 macrophage-like | LPS (0.5–1 µg/mL) | α- and γ-MG | 3–25 µM | inhibition of NO and PGE2 production by α- and γ-MG; iNOS expression reduced by both compounds; COX-2 expression and iNOS enzymatic activity were not affected | [ |
| Rat RBL-2H3 basophilic leukemia | bovine serum albumin | α-, β-, and γ-MG | 20 µM | α-MG significantly inhibited histamine release and blocked cytoplasmic Ca2+ elevation; γ-MG significantly reduced reactive oxygen species; suppressed phosphorylation of Syk, phospholipase C γ1 and γ2 by all mangostins; complete suppression of phosphorylation of Erk ½; JNK ½ and p38 MAPK signaling not altered; slight suppression of | [ |
| Rat C6 glioma cells | A23187 calcium ionophore (10 µM) | γ-MG | 1–30 µM | inhibition of COX-1 and -2 activities and PGE2 release by γ-MG; no effects on MAPK/ERK phosphorylation | [ |
| Rat C6 glioma cells | LPS (10 µg/mL) | γ-MG | 1–30 µM | inhibition of LPS-induced PGE2 release, COX-2 mRNA and protein expression; no effect on COX-1; inhibition of IκB kinase activity; inhibition of IκB degradation; decreased NF-κB activation | [ |
| Rat C6 glioma cells | A23187 calcium ionophore (10 µM) and LPS (1 µg/mL) | Garcinone B | 10–20 µM | inhibition of COX-1 and COX-2 activities and PGE2 release; inhibition of IKK activity and NF-κB-dependent transcription | [ |
| Human Caco-2 enterocyte-like cells | IL-1β (25 µg/mL) | aqueous extract of mangosteen pericarp containing polyphenolic compounds | 50 µmol gallic acid equivalents/L | stimulation of basal PGE2 secretion; no effect on IL-8 secretion or activation of ERK, JNK, and NF-κB | [ |
In vivo anti-inflammatory activities of mangosteen xanthones.
| Animal studies | |||||
|---|---|---|---|---|---|
| Model | Tested compound/product | Delivery route | Dose | Outcomes | Reference |
| rats: carrageenan-induced hind paw edema, cotton pellet implantation, granuloma pouch technique | α-MG, 1-isomangostin, mangostin triacetate | intra-peritoneal, oral | 50 mg/kg | reduction in paw edema volume, granuloma weight, and granuloma pouch exudate | [ |
| rat carrageenan-induced hind paw edema | γ-MG | intra-peritoneal | 10 and 30 mg/kg | concentration dependent inhibition of edema formation | [ |
| rat carrageenan-induced paw edema | α-MG isolated from
| not specified | 9.4 mg/kg | inhibition of edema | [ |
| mouse carrageenan-induced paw edema | α- and γ-MG | oral | 20 mg/kg | inhibition of paw edema formation by α-MG, but not by γ-MG | [ |
| mouse OVA-induced allergic asthma | α- and γ-MG | oral | 10 and 30 mg/kg | both xanthones attenuated inflammatory cell recruitment into the airway; reduced airway hyper-responsiveness; lower levels of Th2 cytokines; attenuated PI3K activity, Akt phosphorylation, and NF-κB activation | [ |
| human subjects with periodontal pockets | pericarp extract | topical | not specified | clinical improvement in periodontal inflammation; subgingival microbial composition altered from diseased to healthy state | [ |
| healthy adults | mangosteen supplement containing mangosteen juice, vitamins, minerals, aloe vera, and green tea | oral | 59 mL/day for 30 days | decreased levels of serum CRP levels; increased ratio of T helper to cytotoxic T cells; elevated serum levels of IL-1α and IL-1β, and complement components C3 and C4 | [ |
| obese subjects | mangosteen juice blend (mangosteen, apple, pear, grape, blueberry, raspberry, strawberry, cranberry and cherry) | oral | 6, 12, and 18 oz/day for 8 weeks | Decreased CRP levels in subjects consuming 18 oz of blended juice; increased levels of IP-10 in subjects consuming 6 and 18 oz of blended juice; no differences in F2 isoprostane and IL-12p70 levels; increased MIP-1 beta in subjects ingesting 18 oz blended juice | [ |
Modulation of signaling pathways related to apoptosis, cell cycle and metastasis by mangosteen xanthones.
| Biological activity | Target/messenger/process | Cell type | Reference |
|---|---|---|---|
| *↓p-ERK1/2; ↓p-JNK1/2 | chondrosarcoma SW1353 | [ | |
| ↓Ψm | leukemia HL60; prostate cancer PC12; colorectal cancer DLD-1; melanoma SK-MEL-28; colorectal HCT116; malignant glioblastoma GBM 8401 | [ | |
| ¥↑Caspase-3 | chondrosarcoma SW1353; colon cancer COLO205; leukemia HL60; prostate cancer PC12; melanoma SK-MEL-28; colorectal HCT116; breast cancer MDA-MB231 | [ | |
| ↑Caspase-8 | chondrosarcoma SW1353; colon cancer COLO205; breast cancer MDA-MB231 | [ | |
| ↓Bcl-2; ↑Bax | chondrosarcoma SW1353 | [ | |
| ↑cytochrome c release | chondrosarcoma SW1353; colon cancer COLO205; leukemia HL60; prostate cancer PC12; breast cancer MDA-MB231 | [ | |
| ↓Akt | chondrosarcoma SW1353; colorectal cancer DLD-1 | [ | |
| ↑p-JNK1/2 | prostate cancer PC12; colorectal cancer DLD-1 | [ | |
| ↑Endonuclease G | colorectal cancer DLD-1 | [ | |
| ↑p-ERK1/2 | colorectal cancer DLD-1 and HCT116 | [ | |
| ↑microRNA-143 | colorectal cancer DLD-1 | [ | |
| ↓NF-κB | colorectal HCT116 | [ | |
| ↑Myc, Max, p53 | colorectal HCT116 | [ | |
| ↓β-catenin | colorectal HCT116 and SW480 | [ | |
| G1 arrest | colorectal cancer DLD-1; melanoma SK-MEL-28; breast cancer MDA-MB231 | [ | |
| ↓cyclins, cdc2 | colorectal cancer DLD-1; breast cancer MDA-MB231 | [ | |
| ↓MMP-2, MMP-9 | prostate carcinoma PC-3; breast adenocarcinoma MCF-7; lung adenocarcinoma A549 | [ | |
| ↓u-PA+ | prostate carcinoma PC-3 | [ | |
| ↓p-JNK1/2 | prostate carcinoma PC-3 | [ | |
| ↓NF-κB | prostate carcinoma PC-3; breast adenocarcinoma MCF-7; lung adenocarcinoma A549 | [ | |
| ↓AP-1 | prostate carcinoma PC-3; breast adenocarcinoma MCF-7 | [ | |
| ↓p-ERK1/2 | breast adenocarcinoma MCF-7; lung adenocarcinoma A549 | [ | |
| ↓ανβ3 integrin/FAK | lung adenocarcinoma A549 | [ |
*↓, decrease; ¥↑, increase; Ψm, mitochondrial membrane potential; +u-PA, urokinase-plasminogen activator.